Table 6.

Associations With Investigation or Intervention in Those With Unattributed Chest Pain and Cardiovascular Risk ≥10% at Baseline in Aurum

	Investigation, OR (95% CI)	New lipid‐lowering prescription,* OR (95% CI)
Age, y
18–44	0.96 (0.88–1.06)	0.80 (0.67–0.96)
45–54	1	1
55–64	0.98 (0.94–1.03)	1.16 (1.07–1.26)
65–74	0.94 (0.89–0.98)	1.27 (1.16–1.38)
75+	0.81 (0.76–0.85)	0.89 (0.80–0.99)
Sex
Men	1	1
Women	0.90 (0.88–0.93)	0.99 (0.93–1.05)
Race
Other ethnic groups	1	1
White	1.19 (1.09–1.31)	1.06 (0.95–1.18)
Deprivation
Least	1	1
2nd	0.95 (0.90–1.00)	0.97 (0.90–1.05)
3rd	0.90 (0.85–0.95)	0.99 (0.91–1.08)
4th	0.84 (0.79–0.90)	1.05 (0.96–1.15)
Most	0.69 (0.63–0.75)	1.04 (0.95–1.13)
Diabetes, type 2	0.85 (0.81–0.89)	1.82 (1.66–2.00)
FH
Angina/heart attack age <60 y	1.45 (1.37–1.53)	1.74 (1.60–1.89)
Chronic kidney disease stage 3–5	0.98 (0.94–1.02)	0.85 (0.77–0.94)
Atrial fibrillation	1.51 (1.39–1.63)	1.13 (0.96–1.32)
Treated hypertension	0.92 (0.89–0.95)	1.05 (1.00–1.11)
Total/HDL ratio
≤4	1	1
4–6	1.04 (1.01–1.08)	1.52 (1.44–1.62)
>6	1.02 (0.96–1.08)	2.68 (2.45–2.95)
Not recorded	0.55 (0.52–0.59)	0.32 (0.29–0.36)
BMI †
Normal	1	1
Underweight	0.79 (0.69–0.89)	0.72 (0.54–0.96)
Overweight	1.10 (1.07–1.14)	1.20 (1.13–1.29)
Obese	1.14 (1.10–1.19)	1.29 (1.19–1.39)

BMI indicates body mass index; FH, family history; HDL, high‐density lipoprotein; and OR, odds ratio.

^*In those with no lipid‐lowering prescription in 24 mo before index date, n=79 726.

^† Missing data means not recorded (not presented here).